Civilization Ventures, a San Francisco, CA-based life science companies focused venture capital firm, closed its second fund, at $35m.
This new vehicle follows Fund I in 2017, where the firm had major portfolio exits with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and the acquisition of Singular Bio by Invitae, Inc. (NYSE: NVTA), a publicly traded company at the forefront of advanced medical genetics.
Led by Shahram Seyedin-Noor, founder and General Partner, Civilization Ventures will use its new capital to power the most innovative life science companies in the world at the forefront of genomics/diagnostics, synthetic biology and digital health/AI.
Prior to starting the fund, Shahram Seyedin-Noor was co-founder, CEO and later Executive Chairman/CBO of Rgenix, a clinical-stage cancer therapeutics company, and CFO/VP of Corporate Development at NextBio, a genomics software company acquired by Illumina in 2013.
FinSMEs
26/08/2020